Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of AMG 133 (Maridebart Cafraglutide) in Adults With Overweight or Obesity With or Without Type 2 Diabetes Mellitus
2022-002470-86Phase 2Active
- Sponsor
- Amgen
- Start
- Oct 2022
- Modality
- Peptide-Protein Conjugates → Peptide Conjugates → Peptides, Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of maridebart cafraglutide in obesity, Overweight and type 2 diabetes mellitus (T2DM) (8 cohorts), sponsored by Amgen. Primary endpoint: Percent change from baseline to week 52 in body weight. Started Oct 2022; status: active.
02
Drugs
maridebart cafraglutide
03
Conditions
obesityOverweighttype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2022-002470-86.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002470-86.